IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.
Employees: 51-200
Total raised: $190M
Founded date: 2015
Investors 5
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| - | 6 Dimensio... | 6dimension... |
| - | Perceptive... | perceptive... |
| - | Canaan Par... | canaan.com |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.05.2019 | IPO | $50M | - |
| 15.03.2018 | Series B | $94M | - |
| 03.05.2016 | Series A | $46M | - |
Mentions in press and media 25
| Date | Title | Description | Source |
| 01.02.2023 | IDEAYA Biosciences to Participate in the 2023 Guggenheim Onc... | SOUTH SAN FRANCISCO, Calif., Feb. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. IDYA, a synthetic... | einpresswi... |
| 12.07.2021 | IDEAYA Announces Closing of Public Offering of Common Stock ... | SOUTH SAN FRANCISCO, Calif., July 12, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) ... | prnewswire... |
| 07.07.2021 | IDEAYA Announces Pricing of Public Offering of Common Stock | SOUTH SAN FRANCISCO, Calif., July 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) t... | prnewswire... |
| 06.07.2021 | IDEAYA Announces Proposed Public Offering of Common Stock | SOUTH SAN FRANCISCO, Calif., July 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) t... | prnewswire... |
| 28.06.2021 | IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Dat... | SOUTH SAN FRANCISCO, Calif., June 28, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA),... | prnewswire... |
| 19.04.2021 | IDEAYA Biosciences Announces Agenda for Inaugural Synthetic ... | SOUTH SAN FRANCISCO, Calif., April 19, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA... | prnewswire... |
| 15.04.2021 | IDEAYA Announces Investor Day Webcast to Review Clinical Dat... | SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA... | prnewswire... |
| 15.04.2021 | IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor ... | SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA... | prnewswire... |
| 23.03.2021 | IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196... | SOUTH SAN FRANCISCO, Calif., March 23, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA... | prnewswire... |
| 11.03.2021 | IDEAYA Announces Presentations at AACR Annual Meeting 2021 f... | SOUTH SAN FRANCISCO, Calif., March 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA... | prnewswire... |
Show more